Patricia Pautier, MD

home / authors / patricia-pautier,-md

Articles

Patricia Pautier, MD, of Institut Gustave Roussy

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

Patricia Pautier, MD
October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in ​uterine and soft tissue leiomyosarcoma.

Read More

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

Patricia Pautier, MD
October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Read More

Dr. Pautier on Remaining Challenges in Advanced Soft Tissue Sarcoma

Dr. Pautier on Remaining Challenges in Advanced Soft Tissue Sarcoma

Patricia Pautier, MD
September 11th 2020

Patricia Pautier, MD, discusses remaining challenges in treating patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Read More

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

Patricia Pautier, MD
September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Read More

Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue Sarcoma

Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue Sarcoma

Patricia Pautier, MD
August 24th 2020

Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need